CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that Elisabet de los Pinos, founder and CEO, will present a company overview at the 15th Annual Needham Healthcare Conference in New York, N.Y.
The presentation will take place on Tuesday, April 12, 2016, at 2:40 p.m. EDT.
About Aura Biosciences
Aura Biosciences is developing a new
class of therapies to target and selectively destroy tumor cells. Its
lead program in ocular melanoma, developed under a CRADA with the
National Cancer Institute (NCI), has been granted orphan drug status by
the U.S. Food and Drug Administration. For more information, visit www.aurabiosciences.com.
